EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

The task force’s deliberations resulted in 11 recommendations, 1 less than in 20195 and 4 less than in the first version in 2010.1 For most of the recommendations the LoE was high and this is shown in table 2. Recommendations 1–5 as well as 7 and 9 remained unchanged and recommendations 11 and 12 from 2019 were brought together as recommendation 11. Although seven recommendations remained unchanged, we will provide a summary of the debates around them in the following section.

Therapy with DMARDs should be started as soon as the diagnosis of RA is made. In light of recent debates about definitions of pre-RA,20–22 the question arose whether the term ‘diagnosis of RA’ is limited to patients with the full picture of the disease or also includes ‘suspected’ RA. However, the majority of the participants felt that ‘suspected RA’ is a field of research with too many uncertainties; that the whole evidence base of RA-treatment rests on a diagnosis (observational studies) or classification of RA (randomised controlled trials, RCTs); and that therefore the management of RA should pertain to those in whom a compelling clinical diagnosis of RA (not necessarily the full classical picture of RA, that we nowadays rarely see) has been made. In this light, the question was also beyond the assignment of this task force but rather appropriate to be dealt with by the task force on the management of early arthritis, whose last update was developed in 2016.23 Consequently, no change was made to this item, it received 100% of the votes and the LoA was 9.9±0.2.

Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient. While there was general agreement with this recommendation, certain questions arose. One of them related to the positioning of remission before low disease activity in the text, given that most patients in practice have established disease and in those low disease activity would be the prime target. However, the EULAR recommendations attempt to follow a logical sequence, which has been to first address a new patient (phase I of the algorithm in figure 1), then a patient in whom a csDMARD has failed and finally a patient in whom a bDMARD or tsDMARD has failed. Hence, since remission is the main target for patients with early disease, remission was placed before low disease activity. ‘Sustained’ remission or low disease activity refers to the maintenance of this state for at least 6 months. While particularly relating to established disease, in some cases of early RA low disease activity may be also be an acceptable therapeutic target.

A point worthy of mentioning in this context is the definition of remission. Since ACR and EULAR provided Boolean-based and index-based remission criteria already a dozen years ago,3 these criteria have been implicitly integrated in all EULAR Task Forces, as pertinent. Importantly, though, and in line with the above and previous notions on the potential limitations of the patient global assessment (PGA) in the context of defining remission,24 after the meeting it became known that ACR and EULAR have endorsed an increase of the PGA threshold in the Boolean definition of remission from 1 to 2 cm on a 10 cm VAS, while continuing to keep swollen and tender joints at a maximum of 1 and C reactive protein (CRP) at a maximum of 1 mg/dL,25 allowing more patients to be defined as in remission without jeopardising good radiographic and functional outcomes,26 a requirement mandated when that task force was set in place.3

Another question raised by the patient research partner during the deliberations related to the issue of tender joint counts (TJC) and PGA in the context of fibromyalgia accompanying RA. As patients may not find it easy to distinguish which of their symptoms are caused by their RA and which by chronic widespread pain, it was mentioned that these scores may be higher, thus preventing patients reaching the defined state of remission when using instruments scoring disease activity that include the TJC and/or PGA. Others argued that item 5 of the updated treat-to-target recommendations very clearly states: ‘The choice of the (composite) measure of disease activity and the target value should be influenced by comorbidities, patient factors and drug-related risks’ and fibromyalgia is explicitly mentioned in this context.4 27 Thus, one simply needs to adhere to the pertinent recommendations to resolve this question. Moreover, not only the PGA but rather every component of available disease activity instruments may be subject to inconsistencies under certain circumstances: the PGA may be influenced by concomitant fibromyalgia and other pain syndromes (chronic widespread pain); swollen and TJCs may be influenced by the concomitant presence of (inflammatory) osteoarthritis; and acute phase reactants (APRs) like CRP and other biomarkers comprising APRs may respond independently of clinical improvement when antibodies to the IL-6 receptors, JAK inhibitors and even TNF-inhibitors are used28–30; and can of course also be elevated by drivers of inflammation that are independent of RA activity, such as infections. Therefore, attention should be paid to every single item in addition to the global score before adapting therapy.

While overtreatment or better: mistreatment due to misdiagnosis should always be considered,31 it is difficult to quantify what the true frequency of overtreatment is, since no reliable data exist in this respect, while undertreatment was recently shown to be a major problem in RA.32 Importantly, low disease activity rather than remission is the prime therapeutic target in patients with established RA.27 Consequently, some Task Force members felt that even for an established patient with RA with fibromyalgia the current landscape of recommendations leaves little space to misjudge a disease activity state or apply instruments inappropriately, if these recommendations are adhered to, allowing the best outcomes for individual patients to be reached. It was also assumed by some that rheumatologists are capable of differentiating between RA activity and fibromyalgia or other potentially confounding matters, an aspect that lends further support to the importance of overarching principle C.

This item was agreed on by 97.8% of the votes with 1 abstention. LoA was 9.8±0.4.

Monitoring should be frequent in active disease (every 1–3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted. Only little discussion arose when this recommendation was addressed. However, it was specifically demanded that the previous task force’s recommendations to use only instruments that include swollen joint counts for follow-up assessment of disease activity should be reiterated. It was also noted that in many countries swollen (and tender) joint counts are assessed by various well-trained, experienced health professionals rather than rheumatologists. All task force members agreed to keep this recommendation unchanged and it received an LoA of 9.5±0.7.

MTX should be part of the first treatment strategy. In the context of this and the subsequent recommendation (to prescribe leflunomide or sulfasalazine when MTX is contraindicated) the question regarding the application of hydroxychloroquine arose, just as during previous task forces’ deliberations. However, reference was made to an RCT published more than 30 years ago, which very clearly showed a substantial difference in progression of joint damage between sulfasalazine and hydroxychloroquine,33 suggesting that the latter may only be a very weak DMARD. Thus, hydroxychloroquine may be used in patients with early, mild disease (ie, without poor prognostic factors) in whom the other three csDMARDs are contraindicated or not tolerated. Of note, hydroxychloroquine is widely used in other diseases, especially SLE,34 but not for the purpose of inhibiting joint damage progression. Consequently, this drug is not mentioned among the recommendations, because the task force did not wish to suggest that MTX could be replaced by hydroxychloroquine.

Hydroxychloroquine is also frequently used when csDMARD combinations are applied, such as triple therapy with MTX plus sulfasalazine and hydroxychloroquine. This strategy has been shown in some previous studies and SLRs to not provide any added benefit but rather convey more adverse events, leading to low persistence rates.35 Since some rheumatologists continue to use triple therapy as an initial treatment modality, the term ‘part of’ was kept in the recommendation, even though the preference of the current and previous Task Forces is on MTX monotherapy in combination with short-term GCs (see below); however, MTX should be used in any case, unless not tolerated or contraindicated, such as in patients with significant renal impairment.

The Task Force had also no route-of-administration preference, although costs have to be considered in line with overarching principle E. Regarding dose and escalation of csDMARDs, it is suggested to refer to previous recommendations where this was addressed in detail. In brief, in the presence of sufficient folic acid supplementation, MTX can be rapidly escalated to about 25 mg once weekly (in line with a relative dose of 0.3 mg/kg body weight for a person of about 80 kg; lower weekly doses in Asia); sulfasalazine has been previously recommended at a dose of 3000 mg per day and leflunomide at a dose of 20 mg per day without loading dose.

The voting led to 100% agreement with the recommendation, the LoA amounted to 9.6±0.8.tas

In patients with a contraindication to MTX (or early intolerance), leflunomide or sulfasalazine should be considered as part of the (first) treatment strategy. This item continued to receive a high LoA, although the question was raised if the term ‘early’ was needed when speaking of intolerance, since any intolerance constitutes a reason for change. However, since this term had been added many years ago with the implication that "early intolerane" would preclude a judgement on the efficacy of MTX and under these circumstances the replacing csDMARD would still be regarded as a first treatment, with a focus on early disease, and as a counterpart to the term ‘contraindication’, it was decided to leave this point as it was. Again, 100% of the participants agreed with this recommendation, which achieved an LoA of 9.1±1.2.

Short-term GCs should be considered when initiating or changing csDMARDs, in different dose regimens and routes of administration, but should be tapered and discontinued as rapidly as clinically feasible. This is the first recommendation that was changed based on a lengthy discussion. Compared with 2019, the words ‘and discontinued’ were added. Over the last years, the use of GCs was increasingly recommended until it became a strong recommendation to use MTX plus (‘+’) GCs. However, ‘short term’ was always an additional mandate and, it must be reiterated that chronic use of GCs is neither meant nor suggested by this recommendation; therefore, ‘short term’ has been placed at the beginning of this item and the time frame is cleary defined as not more than 3 months (table 1). While in 2019 and in previous versions of this document the term ‘tapering’ always had the meaning of a reduction of the GC dose to zero, semantically, tapering is often interpreted as dose reduction, meaning decreasing rather than stopping medication.

The SLR on the use of GCs has clarified that in all studies in which a reduction and stopping scheme was mandated (prespecified), 90% of patients had indeed stopped GCs, and only about 10% were still on GCs after 24 months.14 A meanwhile partly published, individual patient data meta-analysis reporting about 10% of GC use at 6 to 12 months after the end of the bridging scheme was also presented to the Task Force.36 However, these data come from clinical trials, while in real life, as seen in most registries, chronic GC therapy is used in about half of the patients37–39 and, therefore, the updated recommendations call more strongly than ever before to discontinue GCs as rapidly as possible. Inability to discontinue GCs due to persistently active disease suggests that the ongoing DMARD therapy is not sufficiently effective and needs to be amended, in line with the treat-to-target approach that is also strongly recommended by the EULAR Task Force. The SLR on efficacy16 confirmed the excellent efficacy of a combination of csDMARDs with GC as for instance evidenced in the NORD-STAR trial: non-inferiority was shown for csDMARDs+GC versus certolizumab+MTX and tocilizumab+MTX while abatacept+MTX was statistically superior,40 but in this respect it is important to refer to two other trials, namely AMPLE, comparing abatacept with adalimumab41 and EXXELERATE, comparing certolizumab pegol with adalimumab,42 with superimposable results in both studies. Thus, also NORD-STAR revealed clinical similarity between csDMARD+GC therapy and any bDMARD+MTX treatment, with high rates of stringent remission by CDAI at 24 weeks (>40%) for all these therapies.40 Thus, also notions that ACR-EULAR remission can be achieved only rarely are refuted by NORD-STAR. Overall, the Task Force felt strongly, that this recommendation should be upheld but that the discontinuation of GC should be more strictly advised, as is now done. Consequently, rheumatologists are urged to either apply a single parenteral dose of GCs, such as parenteral (intramuscular) methylprednisolone, as a bridging therapy or predefine a tapering and discontinuation scheme when starting oral GC, with stopping GC to be planned upfront within 3 months; by that time, the csDMARD, such as MTX, should have already shown its efficacy. If patients still require GCs on top of csDMARDs to control disease activity, then the ongoing treatment approach should be considered as insufficient and therapy should be changed. If bDMARD therapy is then indicated, GCs should be discontinued, since the combination of bDMARDs plus GC not only unnecessarily extends the duration of GC therapy, but also is associated with more adverse events, such as infections—any dependence on GCs for more than 4 months should be regarded as definitive failure of the respective DMARD. With so many therapies currently available, it should be feasible, at least in affluent countries, to find the right DMARD-treatment, ultimately allowing all patients to stop GCs. On the other hand, the recent GLORIA trial suggests that low-dose, GC therapy over 2 years may not only be efficacious, but also safe in elderly patients, although long-term data are still missing43; also, it must be borne in mind that major safety concerns of GCs (CV diseases, infections, fractures) occur after more than 5 years of use and, therefore, further data from this trial must be awaited. Overall, the place of GCs is not yet resolved in all its facets. Generally, the Task Force felt the term ‘short-term GC treatment’ would apply to GC use for up to 3 months, while ‘long term’ should refer to a treatment duration of 4–6 months. Any use of GC for more than 6 months should be considered ‘chronic GC treatment’ and therefore be designated as such. Importantly, the Task Force recommends GC-bridging when initiating or changing ‘csDMARDs’, which clearly dismisses the use of GCs when bDMARDs or tsDMARDs are used; indeed, bDMARDs and csDMARDs help to avoid chronic GC use and GCs should be discontinued rapidly after their initiation. Thus, also when csDMARDs are changed or initiated in the presence of bDMARDs or tsDMARDs, use of GCs is not warranted.

The Task Force also found that the SLR had not revealed new safety concerns and that the risks of GC, including CV risk, are well established. That up to 60% of patients in registries44–46 and also patients entering RCTs of new drugs in patients with early or established RA are already on GCs as maintenance therapy may be explained partly by either continuing an insufficiently effective DMARD or by lack of adherence to the recommendation on GC cessation by both patients and rheumatologists. Thus, while the Task Force does not recommend adding GCs when starting a bDMARD or tsDMARD (left part of phase II in the algorithm in figure 1), it does recommend GCs when starting another csDMARD (right part of phase II in figure 1).

Another issue relates to flare therapy. The Task Force is of the opinion that GCs are appropriate flare medications, especially if injected locally into a joint. On the other hand, a flare usually suggests that the DMARD is not sufficiently controlling the disease. Thus, if it is a monoarticular or oligoarticular flare, local GC application may be sufficient for control, but if it is a persistent, polyarticular flare, the DMARD therapy should be reassessed. In particular, GCs should not be instituted instead of an escalation to targeted therapies. In this respect, please see also subsequent comments regarding GC use in low income countries.

With respect to the safety of GCs, two important question could not be answered and become part of the research agenda: when studies refer to cumulative doses, does the duration of GC treatment matter? In other words: is the risk the same if patients receive 1200 mg of prednisone (or equivalent) over 3–4 months (ie, short to long-term use) when compared with the same total dose applied intermittently or over 5 years (chronic use)? There were also calls for better education; doctors, patients, health professionals, should better understand the rationale for using GCs as a bridging strategy and realise how important it is to discontinue the GCs. Research should identify barriers and facilitators for discontinuation of GCs. How can we make it more feasible to taper and stop GCs rapidly to reduce long-term use?

The second issue raised relates to a potential bias by indication in registry patients: do rheumatologists treat patients with certain comorbidities preferentially with GCs chronically because they preclude advancement of targeted therapies? Are such comorbidities possibly related to GC safety issues?

A final point of debate involved patients who had been using GC chronically for years—and how to manage this situation? Indeed, as mentioned above, up to 60% of patients with RA in real life use GCs chronically. Further, some patients may self-medicate high doses in case of perceived disease flare and abruptly reduce the dose when improved. Such an approach may lead to further flaring and may jeopardise the success rate of additional treatment options. In these patients, a slow tapering and cessation regimen may have to be applied individually, and another DMARD should be prescribed on flare. Ideally, patients should not be dependent on GCs to control disease activity in this decade where there are more than a dozen effective DMARDs available. However, this concept is not established and patients who may be dependent on chronic GC use have not been sufficiently studied, another important aspect for the research agenda. Of note, EULAR has developed points to consider for managing difficult-to-treat RA47 and patients who need chronic low doses GCs are obviously ‘difficult to treat’. The Task Force is also aware that in countries with poor resources and thus little or no access to targeted therapies, the chronic use of GCs may be the only way to control patients’ disease activity and quality of life. More studies are needed in people with RA from these low income countries, although the availability of biosimilars and generic versions of tsDMARDs may hopefully alleviate this problem.

The strong reiteration of this recommendation in its amended form by the Task Force is reflected by the 91.3% of ‘yes’ votes with 8.7% abstentions and no vote against it. Also, the LoA of 9.3±1.2 was the highest ever given to a recommendation regarding GCs.

If the treatment target is not achieved with the first csDMARD strategy, in the absence of poor prognostic factors, other csDMARDs should be considered. This recommendation remains unchanged and continues to be mostly based on expert opinion. Clearly, there is a need to perform prospective studies and this point has again been placed into the research agenda. Thus, it appears to be a local political problem if after insufficient efficacy of MTX another csDMARD ought to be be used at all, and this should be discussed between the rheumatological societies and the payers. While the EULAR recommendations must be data driven and widely applicable and cannot account for political issues in individual countries, sometimes - such as here - compromises have to be made. Importantly, the EUAR recommendations can be applied as a template for national recommendations and also used to address controversial views of administrators.

Another discussion point relates to combinations of csDMARDs, such as ‘triple therapy’. Based on available evidence, it was decided many years ago that the EULAR recommendations would not advocate these combinations for reasons already stated above, but they also do not strongly recommend against such strategies. These recommendations are meant as a guidance document prepared by numerous experts in the field, but in daily practice and in front of an individual patient the individual rheumatologist must arrive at the best decision together with the patient.

The recommendation as worded in 2019 and before was approved by 97.8% of the voters with 1 abstention; the LoA was only 8.6±1.4, which is the lowest among all recommendations, likely reflecting the lack of sufficient evidence for it.

If the treatment target is not achieved with the first csDMARD strategy, when poor prognostic factors are present, a bDMARD should be added; JAK-inhibitors may be also considered, but pertinent risk factors* must be taken into account. In 2019, JAK inhibitors were considered at a similar level as bDMARDs in terms of effectiveness and safety. However, based on the data of the ORAL-Surveillance trial among patients with RA>50 years of age with cardiovascular risk factors,7 in which more major adverse cardiovascular events (MACEs) and higher malignancy rates with tofacitinib compared with TNF-inhibitors were observed, a change of this recommendation was required. While similar findings were not reported from long-term extension trials and registries,48 49 results of a single RCT convey a higher LoE compared with other non-trial data; moreover, the trial was performed in a population with specific risk factors.

The Task Force arrived at the above formulation after discussion of many pros and cons regarding the use of JAKi. These deliberations are detailed below so that readers can follow the way to the decision. In brief, the majority of the Task Force members were of the opinion that the data on risks due to tofacitinib currently pertain only to patients at risk and that these risk factors should be clearly communicated. On the other hand, the Task Force found no evidence for greater risk of tofacitinib versus TNFi in patients without risk factors. While data for other JAKi do not exist beyond registers and long-term extensions of clinical trials, one cannot exclude that a similar risk could also be associated with non-tofacitinib JAKi when subjected to an outcomes RCT. The previous recommendation was amended based on these considerations.

As always, the EULAR Task Force wishes to be transparent with respect to the process that led to its decision and presents details of the discussions about this recommendation. These were lengthy, because many questions were raised, most of which could not be answered by the SLR data or by the experts present in the room. These questions included: (1) Should a new recommendation interpret the ORAL-Surveillance data as relevant only for tofacitinib, or—in the absence of exonerating RCT data for the other JAKi—as relevant for the entire class of JAKi? (2) Should JAKi be fully eliminated from treatment-phase II and only be recommended for use after bDMARDs have failed? The US FDA has decided along this line50 and suggested to use JAKi only after TNF-inhibitors have failed. (3) Given the abundance of available bDMARDs, should we reserve JAKi for use only after all bDMARD modes of action have failed, in other words: should we create a phase IV in the treatment algorithm?

All these points were addressed in detail and several proposed amendments of the recommendations were discussed. In this respect, also the patient research partner’s views were of particular importance. These comments related to the importance of shared decision making especially under the circumstances of the ORAL Surveillance data, and the advantage of having more therapeutic options available with different modes of action and routes of administration as long as the perceived benefits outweigh the perceived risks. Transparency is key here; a patient can only make an informed decision after being fully told about the benefits and risks. Of note, the patient research partner specifically addressed the importance of not deterring future new drug development as a consequence of restricting the use of all JAKi based on one study solely related to tofacitinib and that it was important JAKi are still prescribed in order to accumulate real-world data on their safety.

When it came to voting on a new or amended recommendation, several options were discussed. The proposal to change ‘tsDMARDs’ into ‘JAK1/2 inhibitors’ or only ‘JAK1 inhibitors’ received so much opposition that it was not further pursued for voting; most of the Task Force members thought that it was currently not possible to make statements on higher or lower risks of JAKi based on their (theoretical) selectivity.

The first voting round then took place between two options. Option 1 proposed to delete ‘or a tsDMARD’ in recommendation 8 and leave this only for use after a bDMARD has failed, in other words to move JAKi to phase III of the treatment algorithm; option 2 suggested placing a semicolon after the current recommendation and then adding: ‘but bDMARDs should be favoured over JAKi in those with pertinent risk factors’. Option 1 received 32% and option 2 attained 68% of the votes. While this voting-result revealed a clear preference, the majority needed for this first round (75%) was not met.

In the subsequent discussion, it was proposed to develop a dual message in this recommendation, to delete ‘or a tsDMARD’ from it and separate the remains from the subsequent statement by a semicolon. The subsequent part would then either read: ‘JAK-inhibitors may also be considered in patients without pertinent risk factors*’ (option 3); or: ‘JAK inhibitors may also be considered in the appropriate patient taking pertinent risk factors* into account” (option 4), with the asterisks defining risk factors in a footnote. Option 3 received 23% of the votes, and option 4 received 72% of the votes, while 5% abstained. Thus, option 4 was agreed to by the appropriate majority, and after some wordsmithing it was formed into the new recommendation 8 as stated above and in table 2. Recommendation 8 now clearly separates bDMARDs from JAKi, but still does not fully refute JAKi at this stage of the treatment cascade. Rather, it calls for a considerate approach to the use of JAKi and mandates a careful evaluation of the risks that individual patients may carry with them, as well as shared decision making after fully informing the patient. The term ‘may be considered’ in conjunction with the ‘must’ regarding assessment of pertinent risk factors best reflects the thinking-process of the Task Force regarding this recommendation.

Finally, a discussion on the risk factors ensued. Was 65 years the appropriate age? What about patients who started a JAKi at age 62 and reached 65 during the course of treatment—would they then have to stop therapy? Are smokers who stopped 10 or 20 years ago at the same risk for malignancy as current smokers? After some discussion on the definition of risk factors, it was decided to focus primarily on the risk definitions mentioned by the European Medicines Agency (EMA), these were added as a footnote to recommendation 8 and comprise age over 65 years, history of current or past smoking, other cardiovascular risk factors, other risk factors for malignancy, and risk factors for thromboembolic events (details are mentioned in the respective footnotes to table 2 and figure 1).51

Of note, the focus on CV and malignancy risk here is a consequence of the recently published data, but it is evident since the introduction of bDMARDs more than 20 years ago that infection risks, especially risks of tuberculosis reactivation or Herpes zoster, has to be taken into account and respective precautious measures initiated as needed. Moreover, in a substudy of ORAL-Surveillance, published several months after the Task Force meeting, an increased infection rate beyond Herpes Zoster was seen for tofacitinib compared with TNF-inhibition.52

Regarding dosing of b/ts DMARDs, the Task Force refers to previous versions of this manuscript and various consensus statements, such as starting with 8 mg/kg of tocilizumab rather than 4 mg/kg, if intravenous dosing is preferred, or the use of 2×500 mg or 1×1000 mg rituximab rather than 2×1000 mg. Further, in the absence of contra-indications (see above), for baricitinib, the 4 mg daily dose, as approved in Europe, has some efficacy advantages especially in patients with long-standing RA compared with the 2 mg daily dose as approved in the USA. Finally, the use of loading doses for certolizumab pegol or sc abatacept may have to be revisited.

The recommendation achieved 100% approval and this is a good example of how discussions and exchanges of thought can lead to a compromise that is viable for everyone in spite of initially opposing views. Consequently, the subsequent LoA of 9.1±1.1 was high.

Many questions raised during the deliberations were considered important topics for the research agenda (box 1).

bDMARDs and tsDMARDs* should be combined with a csDMARD; in patients who cannot use csDMARDs as comedication, IL-6 pathway inhibitors and tsDMARDs* may have some advantages compared with other bDMARDs. No new compelling evidence was gained regarding monotherapy of bDMARDs or tsDMARDs compared with combination therapy. Therefore, the EULAR Task Force continues to advocate the continuation of MTX (or other csDMARDs) when treatment with bDMARDs or JAKi is planned. In this context, it should be borne in mind that once patients have arrived at this stage, they usually have tolerated MTX well and do not need to stop the drug due to intolerance. Moreover, as also repeatedly stated in previous versions of the recommendations, the MTX dose can be reduced to as low as 10 mg weekly to convey the added benefit of combination vs monotherapy.53 54

No textual change was made in this recommendation, which received 100% of the votes and attained an LoA of 9.2±0.9; however, asterisks were added after the words ‘tsDMARDs’ to account for the risk factors addressed in recommendation 8, as will also be done in subsequent recommendations as pertinent.

If a bDMARD or tsDMARD* has failed, treatment with another bDMARD or a tsDMARD* should be considered; if one TNF- or IL-6 receptor inhibitor therapy has failed, patients may receive an agent with another mode of action or a second TNF- or IL-6 receptor inhibitor. Since the SLR revealed that sarilumab can replace tocilizumab and is efficacious also in patients in whom tocilizumab has failed, thus partly answering a previous research question, the old recommendation could be expanded to include IL-6R inhibitors rather than just mentioning TNF-blockers, although only observational or extension data exist for IL-6R inhibitors,55 56 while RCTs have been performed with TNF-blockers.57 58 On the other hand, we still miss data on the efficacy and safety of using a JAKi after another JAKi has failed and this, again, is part of the research agenda. Also, patients who have failed multiple b/tsDMARDS have to be seen as difficult-to-treat RA in line with the respective EULAR definition and points to consider.47 59 Almost 98% of the participants voted for this change with no one against it. The LoA was 9.3±0.8.

After GCs have been discontinued and a patient is in sustained remission, dose reduction of DMARDs (bDMARDs/tsDMARDs and/or csDMARDs) may be considered. This new recommendation has been constructed by combining the last two items from 2019 which read as follows: ‘If a patient is in persistent remission after having tapered GCs, one can consider tapering bDMARDs or tsDMARD, especially if this treatment is combined with a csDMARD.’ And: ‘If a patient is in persistent remission, tapering the csDMARD could be considered.’5 Evidence has emerged indicating that there was no difference in clinical outcome when either a bDMARD or csDMARD was tapered first. It had previously been suggested to start with a reduction of bDMARDs because of the costs involved. However, an economic analysis has revealed that the total costs of tapering csDMARDs first vs tapering anti-TNFs first did not differ.60 Consequently, the Task Force was of the opinion that there is no preferred tapering sequence and this can be left to the discretion of patients and rheumatologists in a shared decision, but still with an open eye on costs, since prices of bDMARDs may vary significantly within and between countries.

In addition, the place of GC tapering was changed. As discussed above for item 6, the term tapering is often misinterpreted and, therefore, the Task Force stipulated that GCs must be ‘discontinued’ before considering tapering other agents. For that reason, the GC part of this recommendation was moved to the beginning of the recommendation.

Importantly, though, there is also compelling evidence that stopping bDMARDs and/or csDMARDs will ultimately lead to flares in most patients.61–63 Therefore, the Task force felt that either dose reduction or interval increase (‘spacing’) is preferred, but completely stopping may not be advisable. Of note, most (though not all) patients who flare after dose reduction can be brought back into a good disease state after reintroduction of the original dose. Also, as discussed in previous versions, tapering of DMARDs should only be started if a patient is in persistent stringent (ACR-EULAR) remission for at least 6 months, although more data may be needed to determine the lowest level of disease activity that provides a good prediction for maintenance of a good state. Finally, it was noted that tapering trials were very heterogeneous and that some standardisation by regulators or professional societies would be needed.

This new recommendation received 95.4% of the votes; 2.3% abstained and 2.3% voted against. The LoA amounted to 9.3±1.1.

All overarching principles and recommendations are summarised in table 2 together with respective footnotes for specific definitions, LoEs, grades of recommendation and LoA. An abbreviated, graphical form of the recommendations is presented in figure 1, also together with respective footnotes. The explanatory part for each individual recommendation in the manuscript is part of the recommendations which only stand in full when these explanations and expansions are taken into account.

A research agenda is shown in box 1. Some points of the old questions have been worked up, others wait to be addressed soon and are repeated here. As indicated above, many new areas for research were opened during the meeting and this is also reflected in box 1.

留言 (0)

沒有登入
gif